Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

Summary

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).

Timeline

Start

2024-06-05

Primary completion

2025-07-29

Completion

2025-07-29

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to early terminate the study following the termination of the parent study (NCT05999799), which met pre-defined futility criterion for efficacy. No safety concerns were identified.”

Drugs

Indications